- Date of occurrence of the event: January 26, 2017
- Company name: OBI Pharma, Inc.
- Relationship to the Company (please enter ”head office” or ”affiliated company”): Head office
- Reciprocal shareholding ratios: N/A
- Name of mass media: N/A
- Content reported: N/A
- Cause of occurrence: China Food and Drug Administration (CFDA) authorized a multi-center Phase III clinical trial in Asia for the novel breast cancer drug Adagloxad Simolenin (OBI-822, also known as OPT-822). The planning of its indication, trial design, number of participants, and trial schedule will be based on comprehensive consideration of the OBI-822 global clinical trial development strategy.
- Countermeasures: Please refer to the information disclosed on mops.twse.com.tw for regarding financial affairs and R&D progress.
- Any other matters that need to be specified: New drug development is a long journey associated with high cost. It is not a guaranteed success, which may increase the risk of investment. Investors shall make prudent judgments and investments.
